<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38596266</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2220-6124</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>25</Day></PubDate></JournalIssue><Title>World journal of nephrology</Title><ISOAbbreviation>World J Nephrol</ISOAbbreviation></Journal><ArticleTitle>Renoprotective strategies.</ArticleTitle><Pagination><StartPage>89637</StartPage><MedlinePgn>89637</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">89637</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.5527/wjn.v13.i1.89637</ELocationID><Abstract><AbstractText>Kidney disease remains a condition with an increasing incidence, high morbidity and mortality associated with cardiovascular events. The incidence of end-stage renal disease is expected to increase. Despite of the technical improvement, dialysis never achieved a full clearance of the blood dialysis. Therefore, the demand for new renoprotective measures has never been greater. Here, we report new strategies for preventing renal damage.</AbstractText><CopyrightInformation>&#xa9;The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raikou</LastName><ForeName>Vaia D</ForeName><Initials>VD</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Doctors'General Clinic, Athens 11257, Greece. vraikou@med.uoa.gr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Nephrol</MedlineTA><NlmUniqueID>101610229</NlmUniqueID><ISSNLinking>2220-6124</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute renal disease</Keyword><Keyword MajorTopicYN="N">Chronic renal disease</Keyword><Keyword MajorTopicYN="N">Pathophysiology</Keyword><Keyword MajorTopicYN="N">Renoprotection</Keyword></KeywordList><CoiStatement>Conflict-of-interest statement: All the author declares no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>10</Day><Hour>4</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38596266</ArticleId><ArticleId IdType="pmc">PMC11000037</ArticleId><ArticleId IdType="doi">10.5527/wjn.v13.i1.89637</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andrassy KM. Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'. Kidney Int. 2013;84:622&#x2013;623.</Citation><ArticleIdList><ArticleId IdType="pubmed">23989362</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99:S1&#x2013;S87.</Citation><ArticleIdList><ArticleId IdType="pubmed">33637192</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention.  Chronic kidney disease in the United States, 2021. Accessed 17 Aug 2021.Available from: https://www.cdc.gov/kidneydisease/publicationsresources/ckd-national-facts.html .</Citation></Reference><Reference><Citation>Szczech LA, Stewart RC, Su HL, DeLoskey RJ, Astor BC, Fox CH, McCullough PA, Vassalotti JA. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease) PLoS One. 2014;9:e110535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4245114</ArticleId><ArticleId IdType="pubmed">25427285</ArticleId></ArticleIdList></Reference><Reference><Citation>Blecker S, Matsushita K, K&#xf6;ttgen A, Loehr LR, Bertoni AG, Boulware LE, Coresh J. High-normal albuminuria and risk of heart failure in the community. Am J Kidney Dis. 2011;58:47&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119712</ArticleId><ArticleId IdType="pubmed">21549463</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, Greene T, Tighiouart H, Matsushita K, Ballew SH, Sang Y, Vonesh E, Ying J, Manley T, de Zeeuw D, Eckardt KU, Levin A, Perkovic V, Zhang L, Willis K. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75:84&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">31473020</ArticleId></ArticleIdList></Reference><Reference><Citation>Niendorf T, Pohlmann A, Arakelyan K, Flemming B, Cantow K, Hentschel J, Grosenick D, Ladwig M, Reimann H, Klix S, Waiczies S, Seeliger E. How bold is blood oxygenation level-dependent (BOLD) magnetic resonance imaging of the kidney? Opportunities, challenges and future directions. Acta Physiol (Oxf) 2015;213:19&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">25204811</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabadi MM, Lee HT. Adenosine receptors and renal ischaemia reperfusion injury. Acta Physiol (Oxf) 2015;213:222&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270901</ArticleId><ArticleId IdType="pubmed">25287331</ArticleId></ArticleIdList></Reference><Reference><Citation>Persson P, Friederich-Persson M, Fasching A, Hansell P, Inagi R, Palm F. Adenosine A2 a receptor stimulation prevents proteinuria in diabetic rats by promoting an anti-inflammatory phenotype without affecting oxidative stress. Acta Physiol (Oxf) 2015;214:311&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">25891445</ArticleId></ArticleIdList></Reference><Reference><Citation>Neymeyer H, Labes R, Reverte V, Saez F, Stroh T, Dathe C, Hohberger S, Zeisberg M, M&#xfc;ller GA, Salazar J, Bachmann S, Paliege A. Activation of annexin A1 signalling in renal fibroblasts exerts antifibrotic effects. Acta Physiol (Oxf) 2015;215:144&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">26332853</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, Tu W. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. N Engl J Med. 2021;385:2507&#x2013;2519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9119310</ArticleId><ArticleId IdType="pubmed">34739197</ArticleId></ArticleIdList></Reference><Reference><Citation>Crews DC. In advanced CKD with poorly controlled hypertension, chlorthalidone reduced BP at 12 wk. Ann Intern Med. 2022;175:JC29.</Citation><ArticleIdList><ArticleId IdType="pubmed">35226524</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SV, Kosiborod M, Wang J, Fenici P, Gannedahl G, LoCasale RJ. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab. 2018;20:2000&#x2013;2003.</Citation><ArticleIdList><ArticleId IdType="pubmed">29577540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">11565517</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashiwagi A, Maegawa H. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J Diabetes Investig. 2017;8:416&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5497037</ArticleId><ArticleId IdType="pubmed">28178390</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS DECLARE&#x2013;TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380:347&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">30415602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">31196815</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380:2295&#x2013;2306.</Citation><ArticleIdList><ArticleId IdType="pubmed">30990260</ArticleId></ArticleIdList></Reference><Reference><Citation>Heerspink HJL, Stef&#xe1;nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sj&#xf6;str&#xf6;m CD, Toto RD, Langkilde AM, Wheeler DC DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pubmed">32970396</ArticleId></ArticleIdList></Reference><Reference><Citation>The EMPA-KIDNEY Collaborative Group. Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388:117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7614055</ArticleId><ArticleId IdType="pubmed">36331190</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer S, Wheeler-Jones C, Elliott J. Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease. J Vet Pharmacol Ther. 2020;43:243&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8614124</ArticleId><ArticleId IdType="pubmed">32128854</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown CA, Rissi DR, Dickerson VM, Davis AM, Brown SA, Schmiedt CW. Chronic Renal Changes After a Single Ischemic Event in an Experimental Model of Feline Chronic Kidney Disease. Vet Pathol. 2019;56:536&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">30895907</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G FIDELIO-DKD Investigators. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219&#x2013;2229.</Citation><ArticleIdList><ArticleId IdType="pubmed">33264825</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8830527</ArticleId><ArticleId IdType="pubmed">35023547</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan N, Rahman A, Nishiyama A. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease. J Hum Hypertens. 2021;35:148&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">32661269</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int. 2004;66:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15200407</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenzini L, Zanotti G, Bonchio M, Rossi GP. Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data. Pharmacol Res. 2021;163:105332.</Citation><ArticleIdList><ArticleId IdType="pubmed">33271294</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YN, Ma SX, Chen YY, Chen L, Liu BL, Liu QQ, Zhao YY. Chronic kidney disease: Biomarker diagnosis to therapeutic targets. Clin Chim Acta. 2019;499:54&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">31476302</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratliff BB, Abdulmahdi W, Pawar R, Wolin MS. Oxidant Mechanisms in Renal Injury and Disease. Antioxid Redox Signal. 2016;25:119&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4948213</ArticleId><ArticleId IdType="pubmed">26906267</ArticleId></ArticleIdList></Reference><Reference><Citation>Raikou VD, Kyriaki D, Gavriil S. Triglycerides to High-Density Lipoprotein Cholesterol Ratio Predicts Chronic Renal Disease in Patients without Diabetes Mellitus (STELLA Study) J Cardiovasc Dev Dis. 2020;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7570173</ArticleId><ArticleId IdType="pubmed">32752179</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunout D, Barrera G, Hirsch S, Lorca E. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of an Omega-3 Fatty Acid Supplement in Patients With Predialysis Chronic Kidney Disease. J Ren Nutr. 2021;31:64&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">32732154</ArticleId></ArticleIdList></Reference><Reference><Citation>Thobani A, Jacobson TA. Dyslipidemia in Patients with Kidney Disease. Cardiol Clin. 2021;39:353&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">34247749</ArticleId></ArticleIdList></Reference><Reference><Citation>Horinouchi Y, Murashima Y, Yamada Y, Yoshioka S, Fukushima K, Kure T, Sasaki N, Imanishi M, Fujino H, Tsuchiya K, Shinomiya K, Ikeda Y. Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease. Life Sci. 2023;321:121590.</Citation><ArticleIdList><ArticleId IdType="pubmed">36940907</ArticleId></ArticleIdList></Reference><Reference><Citation>Satari M, Bahmani F, Reiner Z, Soleimani A, Aghadavod E, Kheiripour N, Asemi Z. Metabolic and Anti-inflammatory Response to Melatonin Administration in Patients with Diabetic Nephropathy. Iran J Kidney Dis. 2021;1:22&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">33492301</ArticleId></ArticleIdList></Reference><Reference><Citation>Yea JH, Yoon YM, Lee JH, Yun CW, Lee SH. Exosomes isolated from melatonin-stimulated mesenchymal stem cells improve kidney function by regulating inflammation and fibrosis in a chronic kidney disease mouse model. J Tissue Eng. 2021;12:20417314211059624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8638070</ArticleId><ArticleId IdType="pubmed">34868540</ArticleId></ArticleIdList></Reference><Reference><Citation>Raikou VD, Kyriaki D. Association between Low Serum Bicarbonate Concentrations and Cardiovascular Disease in Patients in the End-Stage of Renal Disease. Diseases. 2016;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5456320</ArticleId><ArticleId IdType="pubmed">28933414</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonova D. Vascular calcification and metabolic acidosis in end stage renal disease. Hippokratia. 2009;13:139&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765290</ArticleId><ArticleId IdType="pubmed">19918300</ArticleId></ArticleIdList></Reference><Reference><Citation>Garneata L, Stancu A, Dragomir D, Stefan G, Mircescu G. Ketoanalogue-Supplemented Vegetarian Very Low-Protein Diet and CKD Progression. J Am Soc Nephrol. 2016;27:2164&#x2013;2176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4926970</ArticleId><ArticleId IdType="pubmed">26823552</ArticleId></ArticleIdList></Reference><Reference><Citation>Naghshi S, Sadeghi O, Willett WC, Esmaillzadeh A. Dietary intake of total, animal, and plant proteins and risk of all cause, cardiovascular, and cancer mortality: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ. 2020;370:m2412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7374797</ArticleId><ArticleId IdType="pubmed">32699048</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina P, Molina MD, Pallard&#xf3; LM, Torralba J, Escudero V, &#xc1;lvarez L, Peris A, S&#xe1;nchez-P&#xe9;rez P, Gonz&#xe1;lez-Rico M, Puchades MJ, Fern&#xe1;ndez-N&#xe1;jera JE, Gim&#xe9;nez-Civera E, D'Marco L, Carrero JJ, G&#xf3;rriz JL. Disorders in bone-mineral parameters and the risk of death in persons with chronic kidney disease stages 4 and 5: the PECERA study. J Nephrol. 2021;34:1189&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pubmed">33394344</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>